956274-94-5 Usage
Biological Activity
mavatrep is a potent and orally bioavailable antagonist of trpv1 with ic50 value of 4.6 nm [1][2].transient receptor potential vanilloid-1 (trpv1) is a thermosensitive and nonselective cation channel, and is a member of the trp channel superfamily. the channel is activated by acidic ph (<6.8), thermal stimuli (>43℃), and endogenous lipidic mediators (anandamide and oxidative metabolites of linoleic acid) [1].mavatrep is a potent and orally bioavailable trpv1 antagonist. in hek293 cells that stably express human or rat trpv1 (rtrpv1) channels, mavatrep (1 μm) inhibited capsaicin-induced ca2+ influx with ic50 values of 4.6 nm and 21 nm. in whole-cell patch clamp electrophysiology assay, mavatrep concentration-dependently inhibited the activation of htrpv1 channels by ph (5.0) and capsaicin (1 μm) with ic50 values of 6.8 and 23 nm, respectively. mavatrep (0.1 μm) also inhibited 74 ± 8.1% heat-evoked currents mediated by htrpv1 [1].in the cfa model of inflammatory of pain, mavatrep (10 mg/kg po) significantly reversed cfa-induced thermal hypersensitivity with ed50 and ed80 values of 1.8 and 7.8 mg/kg, respectively [1].
references
[1]. parsons wh, calvo rr, cheung w, et al. benzo[d]imidazole transient receptor potential vanilloid 1 antagonists for the treatment of pain: discovery of trans-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1h-benzimidazol-5-yl}-phenyl)-propan-2-ol (mavatrep). j med chem, 2015, 58(9): 3859-3874.
Check Digit Verification of cas no
The CAS Registry Mumber 956274-94-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,6,2,7 and 4 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 956274-94:
(8*9)+(7*5)+(6*6)+(5*2)+(4*7)+(3*4)+(2*9)+(1*4)=215
215 % 10 = 5
So 956274-94-5 is a valid CAS Registry Number.
956274-94-5Relevant articles and documents
Benzo[d]imidazole transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep)
Parsons, William H.,Calvo, Raul R.,Cheung, Wing,Lee, Yu-Kai,Patel, Sharmila,Liu, Jian,Youngman, Mark A.,Dax, Scott L.,Stone, Dennis,Qin, Ning,Hutchinson, Tasha,Lubin, Mary Lou,Zhang, Sui-Po,Finley, Michael,Liu, Yi,Brandt, Michael R.,Flores, Christopher M.,Player, Mark R.
, p. 3859 - 3874 (2015/05/27)
Reported herein is the design, synthesis, and pharmacologic characterization of a class of TRPV1 antagonists constructed on a benzo[d]imidazole platform that evolved from a biaryl amide lead. This design composes three sections: a 2-substituted 5-phenyl headgroup attached to the benzo[d]imidazole platform, which is tethered at the two position to a phenyl tail group. Optimization of this design led to the identification of 4 (mavatrep), comprising a trifluoromethyl-phenyl-vinyl tail. In a TRPV1 functional assay, using cells expressing recombinant human TRPV1 channels, 4 antagonized capsaicin-induced Ca2+ influx, with an IC50 value of 4.6 nM. In the complete Freund's adjuvant- and carrageenan-induced thermal hypersensitivity models, 4 exhibited full efficacy, with ED80 values of 7.8 and 0.5 mg/kg, respectively, corresponding to plasma levels of 270.8 and 9.2 ng/mL, respectively. On the basis of its superior pharmacologic and safety profile, 4 (mavatrep) was selected for clinical development for the treatment of pain.
